Dyax Corp. (DYAX) Receives FDA Approval To Expand Use Of KALBITOR® (Ecallantide) For The Treatment Of Acute Attacks Of Hereditary Angioedema To Patients 12 Years Of Age And Older
4/4/2014 8:13:31 AM
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for KALBITOR (ecallantide), a peptide inhibitor of plasma kallikrein used in the treatment of acute hereditary angioedema (HAE) attacks, to include patients 12 years of age and older. With this approval, KALBITOR is the first and only subcutaneous therapy available to treat acute attacks of HAE in patients 12 years of age and older. KALBITOR is also the only therapy that is not purified from human plasma that has been approved to treat this patient group.
Help employers find you! Check out all the jobs and post your resume.
comments powered by